Skip to main
ACHV

ACHV Stock Forecast & Price Target

ACHV Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Achieve Life Sciences is a late-stage clinical specialty pharmaceutical company with a strong focus on addressing the nicotine dependence epidemic through the development and commercialization of cytisinicline, a naturally occurring alkaloid. The recent Complete Response Letter (CRL) for cytisinicline in smoking cessation, which did not raise any new clinical concerns, provides a more defined regulatory roadmap and supports our positive thesis on the stock. We believe that the company's plan to resubmit the NDA in 4Q26 and potential 1H27 launch, along with its progress in transitioning to a new commercial manufacturing partner, bode well for the success of this product. Risks include 1) Commercial execution risk, 2) Clinical trial risk, 3) Regulatory risk, 4) Financing risk, and 5) Risk of a required partner controlling commercialization efforts.

Bears say

Achieve Life Sciences is currently facing a delay in their PDUFA date, scheduled for June 2026, due to technology transfer completion to Adare Pharma Solutions. This delay has caused the market to price in a potential CMC-only CRL and shift the focus to a resubmission in 4Q26 and potential launch in 1H27. While this presents a favorable risk-reward scenario with potential upside upon approval, the company's sole focus on nicotine dependence and its limited market penetration may pose challenges in the highly competitive smoking cessation market. The financials also show a decline in revenue from $0.20 million in 2019 to $0.01 million in 2020, raising concerns about the company's financial stability.

ACHV has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Achieve Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Achieve Life Sciences (ACHV) Forecast

Analysts have given ACHV a Strong Buy based on their latest research and market trends.

According to 3 analysts, ACHV has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Achieve Life Sciences (ACHV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.